WorldCare Clinical Commences Independent Review of Large Phase III Melanoma Trial

World's Leading Imaging CRO Advances Melanoma Research

Boston, MA,  September 15, 2017 -- WorldCare Clinical (WCC), a leading provider of imaging services in Oncology clinical trials, today announced that it had commenced radiology, dermatology, and oncology central review services on a Phase III international clinical trial to assess a new treatment for melanoma.

Melanoma is the most dangerous form of skin cancer. The main cause of melanoma is intense UV exposure, often resulting in sunburn, especially in those who are genetically predisposed to the disease. Each year in the United States, more than 87,000 people are diagnosed with melanoma and approximately 10,000 people die from the disease.

In the current clinical trial, WCC utilizes integrated teams of board-certified, subspecialists in dermatology, radiology, and oncology from Harvard Hospitals to perform independent assessments of clinical trial data. These physicians use telemedicine techniques to quantify the extent of melanoma on skin photos and radiographic images.

"WCC's unique combination of scientific expertise, operational excellence, state-of-the-art software system, and subspecialty-trained reviewers from the Harvard Hospitals is ideally-suited for clinical trials involving interdisciplinary reviewer teams, such as those required in melanoma studies," stated Aaron Timm, CEO of WorldCare Clinical.

About WorldCare Clinical

WorldCare Clinical is a global imaging CRO that employs scientific expertise, innovative technology, and operational excellence to maximize the precision and accuracy of a blinded independent central review of Phase I – IV clinical trial data. The company has worked with thousands of sites in more than 60 countries. WCC's robust technology platform processes over 250 million images annually (CT, MRI, X-Ray, Echo, US, PET). Originally founded in 1992 by the Massachusetts General Hospital (MGH) Department of Radiology, WorldCare continues to maintain a strategic relationship with the Harvard Hospital System as well as other leading academic institutions.

For more information on WCC's services, please visit our website at or contact:

Thomas O'Donnell

(513) 924-5183

Our Services
888.816.4721 | +1.513.924.5183
We use cookies to help give you the best experience on our website. If you continue without changing your cookie settings, we'll assume you are happy to receive cookies on the website. However, if you would like to, you can change your cookie settings at any time.